BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22190514)

  • 1. SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?
    Furth C; Meseck RM; Steffen IG; Schoenberger S; Denecke T; Henze G; Hautzel H; Hofheinz F; Großer O; Hundsdoerfer P; Amthauer H; Ruf J
    Pediatr Blood Cancer; 2012 Sep; 59(3):475-80. PubMed ID: 22190514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma.
    Schot BW; Pruim J; van Imhoff GW; Sluiter WJ; Vaalburg W; Vellenga E
    Haematologica; 2006 Apr; 91(4):490-5. PubMed ID: 16533726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.
    Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S
    J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.
    Hussien AE; Furth C; Schönberger S; Hundsdoerfer P; Steffen IG; Amthauer H; Müller HW; Hautzel H
    Cancers (Basel); 2015 Jan; 7(1):287-304. PubMed ID: 25635760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
    Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
    Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
    Yoon DH; Baek S; Choi CM; Lee DH; Suh C; Ryu JS; Moon DH; Lee JS; Kim SW
    Clin Cancer Res; 2011 Aug; 17(15):5093-100. PubMed ID: 21673067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
    Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
    Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma?
    Ibrahim F; Gabelloni M; Faggioni L; Padma S; Visakh AR; Cioni D; Neri E
    J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
    Furth C; Steffen IG; Amthauer H; Ruf J; Misch D; Schönberger S; Kobe C; Denecke T; Stöver B; Hautzel H; Henze G; Hundsdoerfer P
    J Clin Oncol; 2009 Sep; 27(26):4385-91. PubMed ID: 19667276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma.
    Wai SH; Lee ST; Cliff ERS; Bei M; Lee J; Hawkes EA; Chong G
    Blood Adv; 2024 Feb; 8(3):736-745. PubMed ID: 38127277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
    Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
    Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
    J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.
    Kanoun S; Tal I; Berriolo-Riedinger A; Rossi C; Riedinger JM; Vrigneaud JM; Legrand L; Humbert O; Casasnovas O; Brunotte F; Cochet A
    PLoS One; 2015; 10(10):e0140830. PubMed ID: 26473950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.